Hookipa Pharma Inc (NASDAQ: HOOK)’s stock price has plunge by 38.95relation to previous closing price of 0.95. Nevertheless, the company has seen a 57.12% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-20 that NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) — NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Is It Worth Investing in Hookipa Pharma Inc (NASDAQ: HOOK) Right Now?
The 36-month beta value for HOOK is also noteworthy at 0.76. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for HOOK is 6.88M, and at present, short sellers hold a 0.19% of that float. The average trading volume of HOOK on May 02, 2025 was 47.18K shares.
HOOK’s Market Performance
The stock of Hookipa Pharma Inc (HOOK) has seen a 57.12% increase in the past week, with a 28.16% rise in the past month, and a -34.00% fall in the past quarter. The volatility ratio for the week is 15.44%, and the volatility levels for the past 30 days are at 12.21% for HOOK. The simple moving average for the past 20 days is 59.90% for HOOK’s stock, with a -55.69% simple moving average for the past 200 days.
Analysts’ Opinion of HOOK
Many brokerage firms have already submitted their reports for HOOK stocks, with RBC Capital Mkts repeating the rating for HOOK by listing it as a “Sector Perform.” The predicted price for HOOK in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on December 20, 2024 of the previous year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see HOOK reach a price target of $48, previously predicting the price at $50. The rating they have provided for HOOK stocks is “Outperform” according to the report published on November 15th, 2024.
BofA Securities gave a rating of “Underperform” to HOOK, setting the target price at $0.50 in the report published on December 02nd of the previous year.
HOOK Trading at 18.19% from the 50-Day Moving Average
After a stumble in the market that brought HOOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.74% of loss for the given period.
Volatility was left at 12.21%, however, over the last 30 days, the volatility rate increased by 15.44%, as shares surge +43.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.26% lower at present.
During the last 5 trading sessions, HOOK rose by +57.12%, which changed the moving average for the period of 200-days by -77.70% in comparison to the 20-day moving average, which settled at $0.8259. In addition, Hookipa Pharma Inc saw -34.33% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for HOOK
Current profitability levels for the company are sitting at:
- -1.17 for the present operating margin
- 0.98 for the gross margin
The net margin for Hookipa Pharma Inc stands at -0.99. The total capital return value is set at -0.89. Equity return is now at value -61.68, with -35.68 for asset returns.
Based on Hookipa Pharma Inc (HOOK), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -87.97. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -25727.5.
Currently, EBITDA for the company is -40.85 million with net debt to EBITDA at 0.95. When we switch over and look at the enterprise to sales, we see a ratio of -0.52. The receivables turnover for the company is 1.86for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.27.
Conclusion
In summary, Hookipa Pharma Inc (HOOK) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
